1
|
Popkin ME, Goese M, Wilkinson D, Finnie S, Flanagan T, Campa C, Clinch A, Teasdale A, Lennard A, Cook G, Mohan G, Osborne MD. Chemistry Manufacturing and Controls Development, Industry Reflections on Manufacture, and Supply of Pandemic Therapies and Vaccines. AAPS J 2022; 24:101. [PMID: 36168002 PMCID: PMC9514697 DOI: 10.1208/s12248-022-00751-9] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2022] [Accepted: 09/02/2022] [Indexed: 01/18/2023] Open
Abstract
This publication provides some industry reflections on experiences from the Chemistry, Manufacturing, and Controls (CMC) development and manufacture and supply of vaccines and therapies in response to the COVID-19 pandemic. It integrates these experiences with the outcomes from the collaborative work between industry and regulators in recent years on innovative science- and risk-based CMC strategies to the development of new, high-quality products for unmet medical needs. The challenges for rapid development are discussed and various approaches to facilitate accelerated development and global supply are collated for consideration. Relevant regulatory aspects are reviewed, including the role of Emergency Use/Conditional Marketing Authorizations, the dialogue between sponsors and agencies to facilitate early decision-making and alignment, and the value of improving reliance/collaborative assessment and increased collaboration between regulatory authorities to reduce differences in global regulatory requirements. Five areas are highlighted for particular consideration in the implementation of strategies for the quality-related aspects of accelerated development and supply: (1) the substantial need to advance reliance or collaborative assessment; (2) the need for early decision making and streamlined engagement between industry and regulatory authorities on CMC matters; (3) the need to further facilitate 'post-approval' changes; (4) fully exploiting prior and platform knowledge; and (5) review and potential revision of legal frameworks. The recommendations in this publication are intended to contribute to the discussion on approaches that can result in earlier and greater access to high-quality pandemic vaccines and therapies for patients worldwide but could also be useful in general for innovative medicines addressing unmet medical needs.
Collapse
Affiliation(s)
- Matthew E. Popkin
- grid.418236.a0000 0001 2162 0389GSK, David Jack Centre for R&D, Park Road, Ware, SG12 0DP UK
| | - Markus Goese
- grid.417570.00000 0004 0374 1269F. Hoffmann-La Roche Ltd, CH-4070 Basel, Switzerland
| | - Diane Wilkinson
- grid.417815.e0000 0004 5929 4381AstraZeneca, Derwent Building, Silk Road Business Park, Charter Way, Macclesfield, SK10 2NA UK
| | - Stuart Finnie
- grid.417815.e0000 0004 5929 4381AstraZeneca, Charter Way, Macclesfield, SK10 2NA UK
| | - Talia Flanagan
- grid.421932.f0000 0004 0605 7243UCB Pharma SA, 1420 Braine l’Alleud, Belgium
| | | | - Alexandra Clinch
- grid.418727.f0000 0004 5903 3819UCB Pharma, 208 Bath Road, Slough, SL1 3WE Berkshire UK
| | - Andrew Teasdale
- grid.417815.e0000 0004 5929 4381AstraZeneca, Chemical Development, Pharmaceutical Technology and Development, Operations, Charter Way, Macclesfield, Macclesfield, SK10 2NA UK
| | - Andrew Lennard
- grid.476413.3Amgen, 4, Uxbridge Business Park, Sanderson Road, Uxbridge, UB8 1DH UK
| | - Graham Cook
- grid.418566.80000 0000 9348 0090Pfizer Ltd., Walton Oaks, Dorking Road, Tadworth, KT20 7NS Surrey UK
| | - Ganapathy Mohan
- grid.417993.10000 0001 2260 0793Merck & Co., Inc., 770 Sumneytown Pike, West Point, PA 19486 USA
| | - Matthew D. Osborne
- grid.473059.cEli Lilly Kinsale Ltd, Dunderrow, Kinsale, P17 NY71 Co. Cork Ireland
| |
Collapse
|